[Answers to questions on rheumatoid arthritis from Practice No. 23].
Mertens
J C
JC
Klinik und Poliklinik fur Innere Medizin, Universitatsspital Zurich, Zurich, Switzerland.
Kaplan
V
V
Ciurea
A
A
D000069594:Abatacept; D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D000068258:Bevacizumab; D003937:Diagnosis, Differential; D000068800:Etanercept; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D018796:Immunoconjugates; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068258:Bevacizumab; D000069283:Rituximab; D000069594:Abatacept; D000068879:Adalimumab; D000068800:Etanercept